AC
CATX icon

AXQ Capital’s Perspective Therapeutics CATX Stock Holding History

AXQ Capital’s Portfolio CATX Stock Details CATX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-17,048
Closed -$71.1K – 1032
2026
Q1 		$71.1K Buy
17,048
+4,299
+34% +$18.2K 0.01% 906
2025
Q4 		$35.1K Buy
12,749
+2,481
+24% +$7.08K 0.01% 698
2025
Q3 		$35.2K Sell
10,268
-10,212
-50% -$37.2K 0.01% 546
2025
Q2 		$70.5K Buy
+20,480
New +$54.1K 0.02% 530

Other funds holding CATX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return
CC
Commodore Capital New York $1.68B AUM 375.52% 1-Year Est. Return
APM
Avidity Partners Management Dallas, Texas $624M AUM 250.2% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
AAA
Affinity Asset Advisors New York $2.21B AUM 431.26% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return
SSC
Spruce Street Capital New York $510M AUM

AXQ Capital's CATX Position: Q2 2026 in Review

AXQ Capital sold out of Perspective Therapeutics (CATX) in Q2 2026, closing a stake of 17,048 shares — an estimated $71.1K sold.

AXQ Capital first reported a position in CATX in Q2 2025 and held it in 4 quarters. The position peaked at $71.1K in Q1 2026. 132 funds tracked by Wall St. Rank hold CATX as of Q2 2026.

  • AXQ Capital reported no remaining Perspective Therapeutics position as of Q2 2026 after selling out during the quarter.
  • AXQ Capital sold 17,048 Perspective Therapeutics shares in Q2 2026, an estimated $71.1K.
  • AXQ Capital first reported a position in Perspective Therapeutics in Q2 2025 and held it in 4 quarters.
  • AXQ Capital's Perspective Therapeutics position peaked at $71.1K in Q1 2026.
  • 132 funds tracked by Wall St. Rank held Perspective Therapeutics as of Q2 2026.

Based on AXQ Capital's 13F filing for Q2 2026, filed 6 Aug 2026.